Beijing-based BioGeometry gets $100M+ for AI drug R&D
A Chinese biotech startup has raised more than $100 million in Series A funding for its AI-driven protein design. BioGeometry, a 4-year-old company headquartered in Beijing, said in a statement Wednesday ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.